-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMIX BIOPHARMA ANNOUNCES 50% ENROLLMENT MILESTONE SURPASSED IN ITS ONGOING RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL, NEXICART-2

Reuters·09/18/2025 17:30:00

Please log in to view news